Cantor Fitzgerald Weighs in on CG Oncology FY2025 Earnings

CG Oncology, Inc. (NASDAQ:CGON) – Research analysts at Cantor Fitzgerald reduced their FY2025 earnings per share estimates for CG Oncology in a report released on Monday, March 31st. Cantor Fitzgerald analyst J. Schimmer now anticipates that the company will post earnings of ($1.78) per share for the year, down from their prior forecast of ($1.52). The consensus estimate for CG Oncology’s current full-year earnings is ($1.31) per share.

CG Oncology (NASDAQ:CGON) last posted its earnings results on Tuesday, March 25th. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.11). The company had revenue of $0.46 million during the quarter, compared to analyst estimates of $0.11 million. CG Oncology had a negative net margin of 10,642.98% and a negative return on equity of 18.97%.

A number of other brokerages have also issued reports on CGON. Morgan Stanley reissued an “overweight” rating and issued a $55.00 target price on shares of CG Oncology in a research report on Friday, March 7th. Royal Bank of Canada reiterated an “outperform” rating and issued a $66.00 price objective on shares of CG Oncology in a report on Friday, December 6th. TD Cowen assumed coverage on CG Oncology in a report on Tuesday, January 7th. They set a “buy” rating for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $75.00 price target on shares of CG Oncology in a research note on Monday. Nine research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $63.88.

CG Oncology Stock Performance

CG Oncology stock opened at $22.24 on Wednesday. The company’s 50 day simple moving average is $27.50 and its 200-day simple moving average is $31.57. CG Oncology has a 1 year low of $21.61 and a 1 year high of $46.99. The company has a market capitalization of $1.69 billion, a price-to-earnings ratio of -15.66 and a beta of 1.60.

Insider Activity at CG Oncology

In other CG Oncology news, Director Leonard E. Post sold 1,000 shares of the business’s stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $29.66, for a total transaction of $29,660.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Institutional Investors Weigh In On CG Oncology

Several institutional investors have recently modified their holdings of CGON. NEOS Investment Management LLC increased its holdings in CG Oncology by 10.9% in the fourth quarter. NEOS Investment Management LLC now owns 8,329 shares of the company’s stock valued at $239,000 after buying an additional 817 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of CG Oncology by 3.5% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,080 shares of the company’s stock valued at $862,000 after acquiring an additional 1,026 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of CG Oncology during the 4th quarter worth about $41,000. Rhumbline Advisers lifted its stake in CG Oncology by 2.2% during the fourth quarter. Rhumbline Advisers now owns 69,016 shares of the company’s stock worth $1,979,000 after purchasing an additional 1,458 shares during the last quarter. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in CG Oncology by 16.4% in the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 12,834 shares of the company’s stock valued at $368,000 after purchasing an additional 1,810 shares in the last quarter. 26.56% of the stock is owned by hedge funds and other institutional investors.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.